Unlock instant, AI-driven research and patent intelligence for your innovation.

A medicine for improving sperm motility and its pharmaceutical use

A technology of use and composition, which is applied in the field of pharmaceutical use of schisandrin A, and can solve problems such as undiscovered drugs

Active Publication Date: 2019-04-09
BEIJING UNIV OF CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the research on spermatogenesis continues, but a drug with low toxicity and high activity has not been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A medicine for improving sperm motility and its pharmaceutical use
  • A medicine for improving sperm motility and its pharmaceutical use
  • A medicine for improving sperm motility and its pharmaceutical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Culture and processing of Leydig cells

[0027] 1 Culture method of Leydig cells

[0028] (1) Take the frozen TM3 cells out of the liquid nitrogen tank, put them into a water bath in a 37°C incubator immediately, and incubate the cryopreserved tubes for 2-3 minutes until they are completely thawed.

[0029] (2) Open the screw cap in the ultra-clean workbench, suck TM3 cells into a high-pressure steam-sterilized centrifuge tube, add 2ml DMEM / F12 high-glucose culture-based cryopreservation tube, wash the cells and transfer them to the centrifuge tube, and then add 2ml of DMEM / F12 high-glucose culture-based centrifuge tube, centrifuge at 800rpm for 5 minutes, discard the supernatant, add 3ml of medium, and repeatedly blow with a pipette to suspend the cells.

[0030] (3) Transfer the cell suspension to a disposable plastic culture bottle in the ultra-clean workbench again, then add about 2ml of medium, shake gently to spread the cells evenly on the bottom of the culture b...

Embodiment 2

[0045] Effects of Schizandrin A on the Vitality of Leydig Cells

[0046] The experiment was divided into normal group, DMSO group, and schisandrin A dosage groups. Schizandrin A dosage settings were as follows: 10 μmol / L, 20 μmol / L, 30 μmol / L, 40 μmol / L, 50 μmol / L, 60 μmol / L, 80 μmol / L. Schizandrin A was dissolved in DMSO.

[0047] After 24 hours of drug action, the supernatant was discarded, and the cells were washed 3 times with PBS. 10 μl of WST-8 solution was added to each well of the 96-well plate. After incubation in the incubator for 1 hour, the OD value was detected at a wavelength of 450 nm by a microplate reader.

[0048] statistical methods

[0049] SPSS 20.0 software was used to perform ONE-WAY ANOVA test on normally distributed data, and the mean value was the mean ± standard deviation Indicates that P<0.05 is a significant difference, which is statistically significant.

[0050] Experimental results

[0051] Compared with the normal group, 5‰DMSO could inhi...

Embodiment 3

[0053] Establishment of oligoasthenospermia model rats

[0054] The model rats were intraperitoneally injected with cyclophosphamide (Cyclophosphamide, CP) 35 mg / kg, once a day, for 5 consecutive days to create a rat model of oligoasthenospermia.

[0055]Grouping and administration of experimental animals: 70 SD rats were randomly divided into 7 groups, namely normal group 1, model group 1, Schizandrin A high, medium and low dose 3 groups, Wuzi Yanzong pill control group 1 and levocarni Ting control group 1 group, 10 rats in each group. Adaptive feeding for 3 days.

[0056] Normal group (NS): the same amount of CP was injected intraperitoneally with normal saline instead of CP for 5 days, and then intragastrically administered with normal saline from the 6th day. Continuous gavage for 2 weeks.

[0057] Model group (CP): intraperitoneal injection of CP 35 mg / kg for 5 days, and intragastric administration with normal saline from the 6th day. Continuous gavage for 2 weeks.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to pharmaceutical application of deoxyschizandrin, in particular relates to an application of deoxyschizandrin in sperm production and sperm activity enhancement. The deoxyschizandrin has drug development value.

Description

technical field [0001] The invention relates to a pharmaceutical application of a medicine, in particular to the pharmaceutical application of schisandrin A. Background technique [0002] Schisandra chinensis is the dry mature fruit of Schisandra chinensis (Turcz.) Baill. or Schisandra sphenanthera Rehd. et Wils. The former is commonly called "Northern Schisandra", and the latter is commonly called "Southern Schisandra". The fruits are picked when they are ripe in autumn, and dried in the sun or steamed to remove the stems and impurities. Tang et al.'s "Xinxiu Materia Medica" contains "the skin and flesh of the five flavors are sweet and sour, the core is hard, and they all have a salty taste", so it has the name of Schisandra. Schisandra is divided into two types: southern and northern. Ancient medical books call it Chuzhu, Xuanji, Huiji, which was first listed in the Shennong Herbal Classic as a top-grade traditional Chinese medicine. It can nourish and strengthen the b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/09A61P15/08
CPCA61K31/09
Inventor 郑燕飞王琦
Owner BEIJING UNIV OF CHINESE MEDICINE